Ovid Therapeutics (OVID) - 2020 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 For the transition period from ______________________ to ______________________ Commission File Number: 001-38085 Ovid Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-5270895 (State or other jurisdiction of incorporation or organization) 1460 Broad ...